| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 84.11 | 2.7% |
| Total Income | 86.42 | 15.3% |
| Expenditure | 67.28 | 7.3% |
| PBT | 19.14 | 686.0% |
| Net Profit | 17.30 | 1022.4% |
| OPM | 27.13% | 3.72pp |
| NPM | 20.01% | 17.95pp |
| EPS | 20.33 | 1017.0% |
Hester Biosciences Q1 FY26 Results: Standalone Performance Down, Consolidated Performance Up
01 Aug 2025 · 1 Aug 2025, 12:34 pm
Summary
Hester Biosciences has announced its Q1 FY26 results. The standalone performance shows a decline in divisional product sales and profit, while the consolidated performance shows an increase in divisional product sales and a significant surge in net profit.
Key Highlights
- 1
Standalone Divisional Product Sales down by 14%
- 2
Standalone Profit down by 7%
- 3
Consolidated Divisional Product Sales up by 2%
- 4
Consolidated Profit up by 131%
- 5
Hester Nepal contributed INR 19.19 million net profit in Q1 FY26
- 6
Hester Africa delivered a net profit of INR 55.02 million in Q1 FY26
- 7
Animal Healthcare Division recorded a 33% decline in sales
- 8
Poultry Healthcare Division recorded a 2% growth
Management Comments
Not provided
Not provided in the document.
Informational and educational content only. Not investment advice.